Conghui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Conghui Wang has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Jianwei Wang
NHC Key Laboratory of System Biology of Pathogens and Christophe Mérieux Laboratory, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College
3 shared publications Li Guo
Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, China
2 shared publicationsLili Ren
NHC Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College, Beijing, China
2 shared publicationsBaoying Huang
MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China
1 shared publicationCaiying Hu
Wuhan Red Cross Hospital, Wuhan, China
1 shared publicationChenyue Li
Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China
1 shared publication
Latest Publications
- 1 September 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 202, 112507
Design, synthesis and anti-inflammatory activity of 3-amino acid derivatives of ocotillol-type sapogenins
- 1 September 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 202, 112507
Design, synthesis and anti-inflammatory activity of 3-amino acid derivatives of ocotillol-type sapogenins
- Top Cited PapersOpen Access
- 3 June 2020
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (5) , 460-470
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Since December 2019, coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread rapidly around the world, with high rates of transmission and substantial mortality. COVID-19 symptoms can range from mild, self-limited respiratory disease to severe progressive pneumonia, multiple organ failure, and even death.1,2 To date, there is no effective treatment or vaccine to contain the disease.
- 3 June 2020
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (5) , 460-470
Top Cited PapersOpen AccessEffect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Since December 2019, coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread rapidly around the world, with high rates of transmission and substantial mortality. COVID-19 symptoms can range from mild, self-limited respiratory disease to severe progressive pneumonia, multiple organ failure, and even death.1,2 To date, there is no effective treatment or vaccine to contain the disease.
- Top Cited Papers
- 7 May 2020
- Published by Springer Nature in Nature
- Vol. 583 (7818) , 830-833
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the corona virus disease 2019 (COVID-19) cases in China and has become a public health emergency of international concern1. Because angiotensin-converting enzyme 2 (ACE2) is the cell entry receptor of SARS-CoV5, we used transgenic mice bearing human ACE2 and infected with SARS-CoV-2 to study the pathogenicity of the virus. Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2. The typical histopathology was interstitial pneumonia with infiltration of significant macrophages and lymphocytes into the alveolar interstitium, and accumulation of macrophages in alveolar cavities. Viral antigens were observed in the bronchial epithelial cells, macrophages and alveolar epithelia. The phenomenon was not found in wild-type mice with SARS-CoV-2 infection. Notably, we have confirmed the pathogenicity of SARS-CoV-2 in hACE2 mice. The mouse model with SARS-CoV-2 infection will be valuable for evaluating antiviral therapeutics and vaccines as well as understanding the pathogenesis of COVID-19.
- 7 May 2020
- Published by Springer Nature in Nature
- Vol. 583 (7818) , 830-833
Top Cited PapersThe pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the corona virus disease 2019 (COVID-19) cases in China and has become a public health emergency of international concern1. Because angiotensin-converting enzyme 2 (ACE2) is the cell entry receptor of SARS-CoV5, we used transgenic mice bearing human ACE2 and infected with SARS-CoV-2 to study the pathogenicity of the virus. Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2. The typical histopathology was interstitial pneumonia with infiltration of significant macrophages and lymphocytes into the alveolar interstitium, and accumulation of macrophages in alveolar cavities. Viral antigens were observed in the bronchial epithelial cells, macrophages and alveolar epithelia. The phenomenon was not found in wild-type mice with SARS-CoV-2 infection. Notably, we have confirmed the pathogenicity of SARS-CoV-2 in hACE2 mice. The mouse model with SARS-CoV-2 infection will be valuable for evaluating antiviral therapeutics and vaccines as well as understanding the pathogenesis of COVID-19.
- 1 January 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 49 (1) , 45-52
Hemin ameliorates influenza pneumonia by attenuating lung injury and regulating the immune response
- 1 January 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 49 (1) , 45-52
Hemin ameliorates influenza pneumonia by attenuating lung injury and regulating the immune response
- Open Access
- 10 February 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 3259
Fragile X mental retardation protein stimulates ribonucleoprotein assembly of influenza A virus
The ribonucleoprotein (RNP) of the influenza A virus is responsible for the transcription and replication of viral RNA in the nucleus. These processes require interplay between host factors and RNP components. Here, we report that the Fragile X mental retardation protein (FMRP) targets influenza virus RNA synthesis machinery and facilitates virus replication both in cell culture and in mice. We demonstrate that FMRP transiently associates with viral RNP and stimulates viral RNP assembly through RNA-mediated interaction with the nucleoprotein. Furthermore, the KH2 domain of FMRP mediates its association with the nucleoprotein. A point mutation (I304N) in the KH2 domain, identified from a Fragile X syndrome patient, disrupts the FMRP–nucleoprotein association and abolishes the ability of FMRP to participate in viral RNP assembly. We conclude that FMRP is a critical host factor used by influenza viruses to facilitate viral RNP assembly. Our observation reveals a mechanism of influenza virus RNA synthesis and provides insights into FMRP functions.
- 10 February 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 3259
Open AccessFragile X mental retardation protein stimulates ribonucleoprotein assembly of influenza A virus
The ribonucleoprotein (RNP) of the influenza A virus is responsible for the transcription and replication of viral RNA in the nucleus. These processes require interplay between host factors and RNP components. Here, we report that the Fragile X mental retardation protein (FMRP) targets influenza virus RNA synthesis machinery and facilitates virus replication both in cell culture and in mice. We demonstrate that FMRP transiently associates with viral RNP and stimulates viral RNP assembly through RNA-mediated interaction with the nucleoprotein. Furthermore, the KH2 domain of FMRP mediates its association with the nucleoprotein. A point mutation (I304N) in the KH2 domain, identified from a Fragile X syndrome patient, disrupts the FMRP–nucleoprotein association and abolishes the ability of FMRP to participate in viral RNP assembly. We conclude that FMRP is a critical host factor used by influenza viruses to facilitate viral RNP assembly. Our observation reveals a mechanism of influenza virus RNA synthesis and provides insights into FMRP functions.